| Abstract: | This invention provides compounds, compositions and methods for treating Autism Spectrum Disorders (ASD) using glycyl-2-methylprolyl-glutamic acid (G-2-MePE) and analogs thereof. Autism Spectrum Disorders include Autism, Autistic Disorder, Asperger Syndrome, Childhood Disintegrative Disorder, Pervasive Developmental Disorder—Not Otherwise Specified (PDD-NOS), Fragile X Syndrome, and Rett Syndrome. Compositions containing compounds include water-soluble formulations, water-in-oil micro-emulsions, water-in-oil coarse emulsions, water-in-oil liquid crystals, nanocapsules, tablets, and orally administered gels. The compounds and compositions of this invention can be administered intravenously, intraventricularly, parenterally, or orally, and can be effective in treating neurodegeneration, promoting neurological function, treating seizure activity and other symptoms of ASD, and can prolong life in animals including human beings having Autism Spectrum Disorders. |
|
Patent landscape, scope, and claims: |
United States Patent 9,212,204 (9,212,204) Claim Scope and US Patent Landscape for G-2-MePE (Glycyl-2-Methyl-L-prolyl-L-glutamate) in Rett Syndrome
Executive summary: US Patent 9,212,204 is directed to a method of treating Rett Syndrome by administering aqueous G-2-MePE orally (and in dependent claims by mucosal dosing) within defined dose ranges and dosing schedules. The claim set also captures (i) specific dose levels, (ii) mucosal administration, (iii) combination therapy with a large roster of neurotrophic, endocrine, cytokine, and psychotropic agents, and (iv) treatment success measured by behavioral and physiologic test endpoints. The practical infringement boundary is therefore broad on dosing and co-therapy, but narrower on the core active ingredient identity, aqueous solution format, and the specific Rett-symptom treatment framing.
What does US Patent 9,212,204 claim for Rett Syndrome treatment with G-2-MePE?
Core independent claim: oral administration of an aqueous solution
Claim 1 requires all elements:
- Exertion: a “method for treating a human being suffering from a symptom of Rett Syndrome”
- Route: “comprising oral administration”
- Formulation: “an effective amount of an aqueous solution of Glycyl-2-Methyl-L-prolyl-L-glutamate (G-2-MePE)”
Scope implications
- The claim is method-of-use: it does not read on compound composition per se. It reads on how the compound is used in treating a human suffering from a Rett symptom.
- “Aqueous solution” is a meaningful limitation. Oral use in capsules/tablets that do not provide an aqueous solution (or where the administered drug form is not an aqueous solution at administration) can become a design-around lever, depending on claim construction and factual alignment.
- “Symptom of Rett Syndrome” is broader than “Rett Syndrome itself,” and can cover individual symptoms (behavioral, motor, respiratory, EEG features) so long as the method ties to Rett-symptom treatment.
Dose range and dosing schedule limitations
Claim 2 narrows claim 1 by requiring the effective amount to be within:
Claim 3 narrows further to a specific regimen:
- ~60 mg/kg twice per day (b.i.d.)
Scope implications
- These are numeric limits that can drive non-infringement arguments if a competitor’s clinical regimen stays outside the range or uses materially different dose and schedule.
- If a competitor argues dose-dependent effects and uses a borderline regimen (close to numeric bounds), infringement risk can turn on interpretation of “about” and on the actual administered amount in clinical practice.
What are the dependent claim coverage points in US 9,212,204 (mucosa, dosing frequency, combinations, endpoints)?
Mucosal administration: oral is broadened
Claim 4 adds:
- “G-2-MePE is administered to a mucosa of said human being.”
Scope implications
- This introduces additional potential routes beyond “oral administration.” In practice, mucosal dosing can be interpreted to cover nasal, buccal, sublingual, or other mucosal delivery depending on the specification and claim construction.
- If a competitor uses mucosal delivery, they may still need to satisfy the independent claim’s “aqueous solution” and “treating Rett symptom” requirements.
Combination therapy roster: Claim 5 creates broad co-therapy coverage
Claim 5 states the method “further comprising administering” a “second therapeutic agent selected from” a long list including:
- IGF-I / IGF-II / GPE and various growth factors
- TGF-β1, activin
- Neurotrophins including BDNF, NGF, NT-3, NT-4
- FGF family (basic/acidic fibroblast growth factor and many FGF homologs)
- BMP-2, glial-derived neurotrophic factors
- Cytokines including LIF, oncostatin M, interleukins
- Interferons (α, β, γ, consensus)
- TNF-α
- Several small-molecule neuroactive agents (examples shown in your text: dizolcipine (MK-801), memantine, selegiline, fluoxetine, risperidone, etc.)
- The claim’s list includes many candidates that are not specific to Rett treatment alone, but the claim requires the combination to be used in the claimed Rett-symptom method.
Scope implications
- Claim 5 is a “conditional” expansion: infringement can occur even if a product is positioned as adjunctive therapy, provided the second agent is on the list and is administered to treat Rett symptoms using G-2-MePE.
- The breadth of listed agents raises the risk that many real-world Rett care regimens could be argued to fall within the co-therapy clause, depending on actual clinical use and what “selected from the group consisting of” is construed to include.
Additional numeric dose embodiments
Claim 6 specifies dose and frequency variants:
- 10 mg/kg three times per day or 30 mg/kg three times per day
Scope implications
- This is an explicit ladder of alternative dosing points. Even if a regimen is outside 1–100 mg/kg (it shouldn’t be, given these are within that range), Claim 6 still matters for competitors who target specific dosing regimens.
Measured outcomes: Claim 7 anchors behavioral and physiologic endpoints
Claim 7 requires that “treatment producess an improvement” assessed by one or more tests, selected from:
Behavioral tests
- Rett Syndrome Natural History/Clinical Severity Scale
- Aberrant Behavior Checklist Community Edition (ABC)
- Vinelands
- Clinical Global Impression of Severity (CGI-S)
- plus carer-completed Caregiver Strain Questionnaire (CSQ)
Physiological tests
- EEG spike frequency
- overall power in EEG frequency bands
- hand movement
- QTc and heart rate variability (HRV)
- respiratory irregularities
Scope implications
- This is typical for method-of-use patents that avoid overly generic “treating” language by tying success to defined endpoints.
- It increases infringement leverage for litigants because clinical trial protocols and outcome reporting can map directly onto the claim’s endpoint list.
How broad is US 9,212,204 as an infringement risk versus narrow design-around routes?
Design-around levers
- Active ingredient identity: the method requires G-2-MePE specifically. Replacing the active with a different peptide or analog reduces alignment with the claim.
- Aqueous solution limitation: competitors using solid oral dosage that is not “aqueous solution” at administration may argue no infringement if construction is strict.
- Dose range: the independent numeric cap is wide (1–100 mg/kg), but specific dependent claims (60 mg/kg b.i.d.; 10 mg/kg t.i.d.; 30 mg/kg t.i.d.) can be avoided by choosing regimens outside those exact structures.
- Measured endpoints: Claim 7 includes “improvement” assessed by selected tests; if the method is practiced and the sponsor does not assess or claim those endpoints, infringement arguments can still exist because Claim 1 does not require endpoints. Claim 7 matters if asserted as dependent claim or for method proof.
Infringement consolidation points
- If the accused therapy uses oral administration of aqueous G-2-MePE to treat Rett symptoms, the case fits Claim 1 directly.
- If the accused therapy also uses mucosal dosing (Claim 4), within 1–100 mg/kg, and especially uses specified dose regimens or co-therapies from the Claim 5 roster, infringement exposure increases.
- The claim structure suggests a litigation strategy where plaintiffs can plead independent and multiple dependent theories depending on the defendant’s clinical protocol.
What does the patent landscape likely look like around US 9,212,204 (Rett peptides, formulation, and endpoints)?
Only the claim text is provided for US 9,212,204; no citation list, related applications, family members, prosecution history, or Orange Book/Biologics listings are included in the prompt. Without that, a complete landscape for:
- related US continuations,
- companion formulation or manufacturing patents,
- foreign equivalents and claim strategy differences,
- FDA submission ties,
- Paragraph IV/ANDA connections,
cannot be produced in an accurate, hard-data way.
What can be stated from the claim scope itself:
- US 9,212,204 is an enforceable method-of-use around a specific active peptide and specific administration/formulation constraints.
- The presence of a large co-therapy list and defined clinical endpoint categories suggests the patent family likely overlaps with:
- earlier or later methods and clinical assessment methodologies in Rett,
- potentially combinatorial treatment concepts,
- and possibly related peptide administration claims tied to G-2-MePE.
But concrete neighboring patent numbers, assignees, filing dates, and expiration dates require sources not included in the input.
Key Takeaways
- US 9,212,204 targets a specific use: treating Rett Syndrome symptoms in humans with oral dosing of an aqueous solution of G-2-MePE.
- Dose and schedule are claim-critical: 1–100 mg/kg (Claim 2), with explicit embodiments at 60 mg/kg b.i.d. (Claim 3) and 10 or 30 mg/kg t.i.d. (Claim 6).
- Route coverage expands via mucosal administration (Claim 4).
- Combination therapy is broad: Claim 5 captures many neurotrophic, cytokine, growth factor, interferon, and neuroactive agents as add-ons, as long as they’re selected from the listed group.
- Clinical endpoints are enumerated in Claim 7, anchoring “improvement” to behavioral and physiologic measures used in Rett research and trials.
FAQs
-
Does US 9,212,204 require oral dosing, or can mucosal administration alone infringe?
Claim 1 requires oral administration; Claim 4 adds mucosal administration as a dependent refinement, so infringement depends on how the asserted claim set is pleaded and construed against the accused regimen.
-
If a competitor uses G-2-MePE but not an “aqueous solution,” is the risk eliminated?
Claim 1 requires an “aqueous solution,” making the aqueous character a key limitation.
-
How much do the numeric dose claims matter versus the general effective-amount language?
Claim 1 is “effective amount” without explicit numeric limits; Claims 2, 3, and 6 add numeric dose structures that become decisive when those dependent claims are asserted.
-
Can the combination-therapy clause expand infringement even if the base therapy is unchanged?
Yes. If G-2-MePE dosing meets Claim 1 and the second agent is among the Claim 5 list, the combination method can fit the dependent claim.
-
Do the behavioral/physiological endpoints need to be used in the accused trial to establish infringement?
Endpoints appear in Claim 7. Independent Claim 1 does not require those endpoints, but Claim 7 can drive evidence and pleading leverage when asserted.
References
No external sources were provided or cited in the prompt; therefore no reference list can be generated without introducing uncited factual material.
More… ↓
⤷ Start Trial
|
